LX2931

LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL) . LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the treatment of autoimmune diseases, especially rheumatoid arthritis[1].

Product Specifications

CAS Number

[948840-25-3]

UNSPSC

12352005

Target

LPL Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Others

Assay Protocol

https://www.medchemexpress.com/lx2931.html

Purity

99.9

Solubility

DMSO : 100 mg/mL (ultrasonic; warming)

Smiles

OC[C@@H](O)[C@@H](O)[C@@H](C1=CN=C(/C(C)=N/O)N1)O

Molecular Formula

C9H15N3O5

Molecular Weight

245.23

References & Citations

[1]Bagdanoff J T, et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E) -1- (4- ((1 R, 2 S, 3 R) -1, 2, 3, 4-tetrahydroxybutyl) -1 H-imidazol-2-yl) ethanone oxime (LX2931) and (1 R, 2 S, 3 R) -1- (2- (isoxazol-3-yl) -1 H-imidazol-4-yl) butane-1, 2, 3, 4-tetraol (LX2932) [J]. Journal of medicinal chemistry, 2010, 53 (24) : 8650-8662.